The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy

Wang, Hui‐Ching; Moi, Sin-Hua; Chan, Leong‐Perng; Wu, Chun‐Chieh; Du, Jeng-Shiun; Liu, Peilin; Chou, Meng-Chun; Wu, Che‐Wei; Huang, Chih-Jen; Hsiao, Hui‐Hua; Pan, Mei-Ren; Chen, Li-Tzong

doi:10.1038/s12276-023-00984-4

Cited by 2 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could also imply that TMB thresholds may differ depending on the clinical stage and extent of prior therapy in different cancers. Studies have indicated predictability in anticipating responses to ICIs in neoadjuvant or early-stage scenarios across various cancer types, including but not limited to NSCLC, melanoma, breast cancer, and HNSCC [106,[150][151][152]. A study by Niknafs, N. and colleagues has shown an association between underlying molecular alterations and the emergence of a persistent TMB that is linked to a favorable response to ICIs [153].…”

Section: Additional Considerations For Futurementioning

confidence: 99%

Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies

Ahmed,

Das,

Shin

et al. 2023

Cancers

View full text Add to dashboard Cite

A standardized assessment of Tumor Mutational Burden (TMB) poses challenges across diverse tumor histologies, treatment modalities, and testing platforms, requiring careful consideration to ensure consistency and reproducibility. Despite clinical trials demonstrating favorable responses to immune checkpoint inhibitors (ICIs), not all patients with elevated TMB exhibit benefits, and certain tumors with a normal TMB may respond to ICIs. Therefore, a comprehensive understanding of the intricate interplay between TMB and the tumor microenvironment, as well as genomic features, is crucial to refine its predictive value. Bioinformatics advancements hold potential to improve the precision and cost-effectiveness of TMB assessments, addressing existing challenges. Similarly, integrating TMB with other biomarkers and employing comprehensive, multiomics approaches could further enhance its predictive value. Ongoing collaborative endeavors in research, standardization, and clinical validation are pivotal in harnessing the full potential of TMB as a biomarker in the clinic settings.

show abstract

Section: Additional Considerations For Futurementioning

confidence: 99%

Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies

Ahmed,

Das,

Shin

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…However, there are still many patients who do not benefit from pembrolizumab treatment ( 7 ). Moreover, the five-year overall survival rate for individuals with HNSC continues to be < 50% ( 8 ). Therefore, there’s an urgent need to comprehensively investigate the complexities of the TME and discover new targets for therapeutic intervention.…”

Section: Introductionmentioning

confidence: 99%

TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion

Wu,

Fu,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectiveAs a pseudokinase, Tribbles Pseudokinase 3 (TRIB3) is implicated in a wide array of biological processes, including cell signal transduction, metabolic regulation, stress responses, and immune regulation. While its significant role in the immune regulation of certain cancers is well-established, the specific functions and impact of TRIB3 in head and neck squamous cell carcinoma (HNSC) remain unclear.MethodsThe data of RNA-sequence was acquired from the TCGA database to analyze the expression patterns of TRIB3 and elucidate its prognostic value in HNSC patients. Furthermore, the correlation between TRIB3 and tumor mutation burden, clinical data, immune checkpoint genes, and immune cell infiltration was explored. Moreover, the TRIB3 location in tumor tissues and subcellular structures was identified via Tisch in the HPA database, and the potential protein interaction molecules for TRIB3 were elucidated in the STRING database. The potential TRIB3 gene function was assessed using gene set enrichment analysis (GSEA), whereas the TRIB3 expression levels in clinical HNSC samples were verified by RT-qPCR and immunohistochemistry. the role of TRIB3 in enhancing the malignant behavior of HNSC cells was validated in vitro through a series of methods including RT-qPCR, CCK8 assay, wound healing assay, and transwell assay.ResultsIt was revealed that TRIB3 was significantly overexpressed in the nucleus and cytoplasm of HNSC. Furthermore, this overexpression markedly enhanced the migration ability of tumor cells. As an independent prognostic factor, TRIB3 was associated with advanced tumor T stage and was significantly involved with tumor mutation burden and immune cell infiltration in HNSC. Moreover, it was observed that TRIB3 was not a predicted factor for PD1/PDL1 and ATL4 inhibitor treatment; however, it was substantially correlated with various immune evasion-related genes in HNSC.ConclusionTRIB3 could serve as a potential prognostic marker for HNSC and might be a key gene mediating HNSC immune evasion.

show abstract

The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy

Cited by 2 publications

References 43 publications

Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies

Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies

TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion

Contact Info

Product

Resources

About